Invitae partners with BridgeBio for discovery of rare disease therapeutics

Invitae (NVTA) announced a partnership with BridgeBio Pharma (BBIO) designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. The agreement expands upon the longstanding partnership between the two companies to combine the strengths of BridgeBio’s deep expertise in rare disease research and development of therapeutics, and Invitae’s rare disease enriched dataset and analytical capabilities. Invitae has provided clinical testing for more than 4M patients, generating an extensive dataset that is uniquely positioned to deepen insights on patients with genetic-driven disease.